You are here

Firdapse Approved for Treatment of Lambert-Eaton Myasthenic Syndrome

First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection

Firdapse (amifampridine, Catalyst Pharmaceuticals) tablets have been approved by the FDA for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. The rare autoimmune disorder affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients.

Around three in one million individuals worldwide are believed to have LEMS. Patients suffer from significant weakness and fatigue that often causes great difficulties with daily activities. LEMS may be associated with other autoimmune diseases, but typically occurs in patients with cancer such as small cell lung cancer.

In two clinical trials, patients receiving amifampridine experienced a greater benefit than those taking placebo. The most common side effects reported were paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms. In addition, seizures have been observed in patients with no history of seizures.

The FDA granted amifampridine priority review, breakthrough therapy, and orphan drug designations.

Source: FDA, November 28, 2018

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial